Ticlopidine hydrochloride tablets are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke.

Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (seeBOXED WARNING andWARNINGS), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.

as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (seeCLINICAL TRIALS).

---

Cerebrovascular accident -- sudden neurologic impairment due to a cerebrovascular disorder, either an arterial occlusion or an intracranial hemorrhage.

Thrombus --

Hematological Disease -- Disorders of the blood and blood forming tissues.

Purpura, Thrombotic Thrombocytopenic -- An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE.

Agranulocytosis -- A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).

Thrombosis -- Formation and development of a thrombus or blood clot in the blood vessel.

The use of ticlopidine hydrochloride is contraindicated in the following conditions: Hypersensitivity to the drug Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either TTP or aplastic anemia Presence of a hemostatic disorder or active pathological bleeding (such as bleeding peptic ulcer or intracranial bleeding) Patients with severe liver impairment

---

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

Hematological Disease -- Disorders of the blood and blood forming tissues.

Neutropenia -- A decrease in the number of neutrophilic leukocytes in the blood. (Dorland, 27th ed)

Thrombocytopenia -- A subnormal level of BLOOD PLATELETS.

Aplastic Anemia -- A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.

Blood Coagulation Disorders -- Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.

Vascular Hemostatic Disorders -- Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS.

PEPTIC ULCER HEMORRHAGE -- Bleeding from a PEPTIC ULCER that can be located in any segment of the GASTROINTESTINAL TRACT.

INTRACRANIAL HEMORRHAGE -- Bleeding within the cranium.

Hepatic impairment --

Neutropenia may occur suddenly.

Bone-marrow examination typically shows a reduction in white blood cell precursors.

After withdrawal of ticlopidine, the neutrophil count usually rises to >1200/mm 3 within 1 to 3 weeks.

The following US Branded drugs contain Ticlopidine hydrochloride

---

TICLID -- ROCHE PALO ALTO LLC